SNCA and early-onset autosomal dominant Alzheimer disease: Prasinezumab (rank 1 among biologics, investigational anti-α-synuclein antibody) achieved the highest network score among large molecule therapeutics through direct engagement of protein aggregation pathways shared between Parkinson’s disease and Alzheimer’s disease.